Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 8Recruiting 6Withdrawn 3Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Lymphoid 1

Conditions

Multiple Myeloma 4Recurrence 3Solid Tumor Malignancy 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdoid Tumor 1Recurrent Squamous Cell Lung Carcinoma 1Neurofibrosarcoma 1Neoplasm, Residual 1Lymphoma, Large B-Cell, Diffuse 1Liposarcoma 1Immunoglobulin Light-chain Amyloidosis 1Central Nervous System Neoplasms 1Amyloidosis 1Alzheimer Disease 1

Interventions

Dexamethasone 14Rituximab 6Cytarabine 5venetoclax 4Lenalidomide 4Bortezomib 4Bendamustine Hydrochloride 4selinexor 3pomalidomide 3pembrolizumab 3ibrutinib 3fludarabine 3carfilzomib 3Paclitaxel 3Gemcitabine 3Drug Therapy 3Cyclophosphamide 3Calcium Dobesilate 3ixazomib 2gilteritinib 2fludarabine phosphate 2elotuzumab 2daratumumab 2belinostat 2Tablets 2Surveys and Questionnaires 2Panobinostat 2Oxaliplatin 2Granulocyte Colony-Stimulating Factor 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Recurrence × selinexor × Clear all
NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Karyopharm Therapeutics Inc

Phase 1/2 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02389543 2023-01-26

SLAM

Karyopharm Therapeutics Inc

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

NCT05170789 2022-05-04

ESdRRMM

Tulane University

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡